Suspected Ticagrelor-Induced Bullous Fixed Drug Eruption

Seecheran, Rajeev; Seecheran, Valmiki; Persad, Sangeeta; Seecheran, Naveen

doi:10.7759/cureus.13890

Cited by 3 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The case reported by Quinn et al demonstrated very similar skin biopsy findings showing perivascular lymphocytic infiltrates compared to our patient but did not comment on necrotic keratinocytes as seen in our biopsy [3]. The four other reports showed different dermatological reactions with one case of exanthematous pustulosis [5], one case of eccrine hidradenitis [6], one case of a bullous fixed drug eruption [7], and a case of Sweet syndrome [8]. These cases are described in Table 1.…”

Section: Discussionsupporting

confidence: 81%

Generalized Drug Eruption Secondary to Ticagrelor: A Case Report and Review of the Literature

Akdogan¹,

Chen²,

Varón³

et al. 2023

Cureus

View full text Add to dashboard Cite

Currently, guidelines recommend ticagrelor over clopidogrel as part of dual antiplatelet therapy with aspirin in treating individuals with acute coronary syndrome. As there is an increased usage of ticagrelor, it is important to keep in mind uncommon adverse events, including hypersensitivity skin reactions. To date, only a few studies have been published regarding ticagrelor-induced skin eruptions. Additionally, there is no consensus on antiplatelet therapy management after a hypersensitivity reaction to antiplatelet agents. Hereinafter, we describe a case of an 81-year-old female who presents with a diffuse erythematous hypersensitivity eruption, including palms and soles, secondary to ticagrelor use. Ticagrelor transitioned to clopidogrel, and the patient was started on steroid taper with an antihistamine. The patient's rash progressively improved after the treatment. Our case demonstrates a rare adverse effect of ticagrelor, which needs prompt diagnosis and switching to one of the thienopyridines to prevent thrombosis.

show abstract

Section: Discussionsupporting

confidence: 81%

Generalized Drug Eruption Secondary to Ticagrelor: A Case Report and Review of the Literature

Akdogan¹,

Chen²,

Varón³

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…Fixed drug eruption is recognized as repeatedly erythematous pigmented plaques following the same causative agents between 30 minutes and eight hours (on average two hours). Blisters occasionally occur on fixed drug eruptions [ 4 ] and can also spread widely and cause systemic symptoms including fever [ 5 ]. These clinical features might resemble Stevens-Johnson syndrome or toxic epidermal necrolysis.…”

Section: Discussionmentioning

confidence: 99%

Fixed Drug Eruption Caused by Garenoxacin: A Case Report and Literature Review

Hara,

Saito-Sasaki,

Sawada

2023

Cureus

View full text Add to dashboard Cite

A new quinolone antibiotic called garenoxacin was developed in Japan. Garenoxacin is known to produce cutaneous adverse effects, particularly fixed drug eruption in Japan, despite several reports of cutaneous adverse events in English-language literature. However, English-language literature has not yet reported that fixed drug eruption is a common clinical manifestation of garenoxacin-induced drug eruption. In this article, we present a case of multiple fixed drug eruptions and review the literature on case reports of drug eruptions caused by garenoxacin.

show abstract

“…Table 1 summarizes the clinical features of these patients. 5–11 All 7 patients were male who were 44–73 years of age; 4 presented with acute coronary syndrome, whereas 2 had stable angina, and 5 of 6 patients in the case reports had undergone a PCI with a drug-eluting stent. Hypersensitivity manifestations included rash (n = 4), urticaria (n = 1), angioedema (n = 2), periorbital edema (n = 1), and hemorrhagic bullae (n = 2).…”

mentioning

confidence: 99%